2024
Noninvasive in vivo photoacoustic detection of malaria with Cytophone in Cameroon
Yadem A, Armstrong J, Sarimollaoglu M, Kiki Massa C, Ndifo J, Menyaev Y, Mbe A, Richards K, Wade M, Zeng Y, Chen R, Zhou Q, Meten E, Ntone R, Tchuedji Y, Ullah S, Galanzha E, Eteki L, Gonsu H, Biris A, Suen J, Boum Y, Zharov V, Parikh S. Noninvasive in vivo photoacoustic detection of malaria with Cytophone in Cameroon. Nature Communications 2024, 15: 9228. PMID: 39455558, PMCID: PMC11511992, DOI: 10.1038/s41467-024-53243-z.Peer-Reviewed Original ResearchConceptsClearance of parasitemiaDetection of malariaMalaria-infected red blood cellsDiagnosed symptomatic casesCross-sectional cohortUncomplicated malariaMalaria diagnosticsMalaria infectionRed blood cellsSymptomatic casesTarget antigenAsymptomatic reservoirCameroonian adultsFlow cytometer platformBlood samplesReservoir of infectionBlood cellsLack sensitivityLongitudinal cohortMolecular assaysMalariaIRBCPoint-of-careCohortQuantitative PCRPersistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children
Goodwin J, Kajubi R, Wang K, Li F, Wade M, Orukan F, Huang L, Whalen M, Aweeka F, Mwebaza N, Parikh S. Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children. Nature Communications 2024, 15: 3817. PMID: 38714692, PMCID: PMC11076639, DOI: 10.1038/s41467-024-48210-7.Peer-Reviewed Original ResearchConceptsDay 7 lumefantrine concentrationsArtemether-lumefantrine treatmentRing-stage parasitesEarly post-treatmentEarly post-treatment periodArtemether-lumefantrineArtemisinin resistanceDay regimenMulticlonal infectionsEfficacious therapyFollow-upRandomized trialsPersistent clonesTransmission settingsEffective treatmentPost-treatment periodRegimensAntimalarial studiesStandard diagnosticsStandard 3DaysPost-treatmentChildrenTreatmentTherapy
2023
Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi
Nyangulu W, Mungwira R, Divala T, Nampota-Nkomba N, Nyirenda O, Buchwald A, Miller J, Earland D, Adams M, Plowe C, Taylor T, Mallewa J, van Oosterhout J, Parikh S, Laurens M, Laufer M. Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi. Malaria Journal 2023, 22: 32. PMID: 36707795, PMCID: PMC9881508, DOI: 10.1186/s12936-023-04466-w.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyLumefantrine levelsTreatment failureDrug-drug interactionsACPR ratesMalaria infectionTrimethoprim-sulfamethoxazolePCR correctionTreatment efficacyUndetectable HIV RNA viral loadEfavirenz-based antiretroviral therapyHIV RNA viral loadUncomplicated Plasmodium falciparum malariaHuman immunodeficiency virus (HIV) infectionArtemether-lumefantrine efficacyCohort of PWHEfavirenz-based regimensImmunodeficiency virus infectionRNA viral loadPlasmodium falciparum malariaMalaria treatment failurePopulation of adultsRandom-effects modelTherapeutic efficacy monitoringLumefantrine exposure
2022
Moving towards malaria elimination with safer treatment for children with G6PD deficiency
Boum Y, Moukoko C, Parikh S. Moving towards malaria elimination with safer treatment for children with G6PD deficiency. The Lancet Infectious Diseases 2022, 23: 388-390. PMID: 36462525, DOI: 10.1016/s1473-3099(22)00724-1.Peer-Reviewed Original ResearchImpact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda
Kay K, Goodwin J, Ehrlich H, Ou J, Freeman T, Wang K, Li F, Wade M, French J, Huang L, Aweeka F, Mwebaza N, Kajubi R, Riggs M, Ruiz‐Garcia A, Parikh S. Impact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. Clinical Pharmacology & Therapeutics 2022, 113: 660-669. PMID: 36260349, PMCID: PMC9981240, DOI: 10.1002/cpt.2768.Peer-Reviewed Original ResearchConceptsLopinavir-ritonavirLumefantrine concentrationsSensitive parasitesRecurrence riskPopulation PK/PD modelArtemether-lumefantrine treatmentTrimethoprim-sulfamethoxazole prophylaxisPK/PD modelPopulation PK modelFirst-order absorptionHigh transmission regionsAntiretroviral regimensLumefantrine exposureLumefantrine susceptibilityPfcrt K76Pfmdr1 N86Suboptimal dosingArtemether-lumefantrineTwo-compartment modelHIV statusRecurrent infectionsCombination therapyDrug exposurePrimary treatmentArtemisinin resistanceClinical characteristics of Plasmodium falciparum infection among symptomatic patients presenting to a major urban military hospital in Cameroon
Hodson DZ, Mbarga Etoundi Y, Mbatou Nghokeng N, Mohamadou Poulibe R, Magne Djoko S, Goodwin J, Cheteug Nguesta G, Nganso T, Armstrong JN, Andrews JJ, Zhang E, Wade M, Eboumbou Moukoko CE, Boum Y, Parikh S. Clinical characteristics of Plasmodium falciparum infection among symptomatic patients presenting to a major urban military hospital in Cameroon. Malaria Journal 2022, 21: 298. PMID: 36273147, PMCID: PMC9588226, DOI: 10.1186/s12936-022-04315-2.Peer-Reviewed Original ResearchConceptsP. falciparum infectionPopulation attributable risk percentFalciparum infectionPlasmodium falciparum infectionYears of ageClinical characteristicsUrban hospitalMilitary HospitalAttributable risk percentHigher positivity rateLikelihood ratioRapid diagnostic testsMajor urban hospitalRural African settingConclusionsThe prevalenceHigh feverSymptomatic patientsHemoglobin levelsAnemia prevalenceSevere anemiaEmergency departmentVenous samplesClinical surveyPositivity rateWHO definitionThe Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial
Whalen ME, Kajubi R, Goodwin J, Orukan F, Colt M, Huang L, Richards K, Wang K, Li F, Mwebaza N, Aweeka FT, Parikh S. The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial. Clinical Infectious Diseases 2022, 76: 443-452. PMID: 36130191, PMCID: PMC9907485, DOI: 10.1093/cid/ciac783.Peer-Reviewed Original ResearchConceptsArtemether-lumefantrineReinfection riskArtemisinin-based combination therapyDay 7 levelsOverall drug exposureHigh transmission settingsYoung childrenAntimalarial exposureUncomplicated malariaExtended regimenRecurrent parasitemiaControlled TrialsPrimary outcomeCombination therapyKaplan-MeierDrug exposureTotal episodesUgandan childrenArtemisinin resistanceLumefantrine concentrationsPharmacodynamic studiesHigh riskPharmacokinetic parametersRecurrence riskDay 7Towards rainbow portable Cytophone with laser diodes for global disease diagnostics
Jawad H, Yadem A, Menyaev Y, Sarimollaoglu M, Armstrong J, Watanabe F, Biris A, Stumhofer J, Nedosekin D, Suen J, Parikh S, Zharov V. Towards rainbow portable Cytophone with laser diodes for global disease diagnostics. Scientific Reports 2022, 12: 8671. PMID: 35606373, PMCID: PMC9126638, DOI: 10.1038/s41598-022-11452-w.Peer-Reviewed Original ResearchConceptsPlasmodium yoelii murine modelDetect infected cellsMalaria-infected erythrocytesDiagnosis of melanomaMalaria progressionSickle anemiaMurine modelDiagnosis of cancerMelanoma cellsEarly diagnosisCardiovascular disordersIn vivoEarly diagnosis of cancerInfected cellsIn vitroBlood backgroundDisease markersRed clotsMelanomaHemozoinMarkersSelectable markerBacteremiaCellsAnemia
2021
Design and analysis of a 2-year parallel follow-up of repeated ivermectin mass drug administrations for control of malaria: Small sample considerations for cluster-randomized trials with count data
Jackson CL, Colborn K, Gao D, Rao S, Slater HC, Parikh S, Foy BD, Kittelson J. Design and analysis of a 2-year parallel follow-up of repeated ivermectin mass drug administrations for control of malaria: Small sample considerations for cluster-randomized trials with count data. Clinical Trials 2021, 18: 582-593. PMID: 34218684, PMCID: PMC8478782, DOI: 10.1177/17407745211028581.Peer-Reviewed Original ResearchConceptsIvermectin mass drug administrationMass drug administrationCluster-randomized trialControl of malariaCluster-randomized trial designDrug AdministrationCrossover designMixed effects modelsTrial designStudy designCluster-level analysisSmall sample sizeCluster-level summariesCluster-level interventionsParallel trialRisk of harmPrimary analysisMalariaAdministrationMixed-effects modelsTrialsLevel interventionsSample sizeAdditional evaluationParallel design
2020
Molecular surveillance of antimalarial partner drug resistance in sub-Saharan Africa: a spatial-temporal evidence mapping study
Ehrlich HY, Jones J, Parikh S. Molecular surveillance of antimalarial partner drug resistance in sub-Saharan Africa: a spatial-temporal evidence mapping study. The Lancet Microbe 2020, 1: e209-e217. PMID: 33089222, PMCID: PMC7575134, DOI: 10.1016/s2666-5247(20)30094-x.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyPartner drug resistanceDrug resistanceSurveillance dataDrug resistance surveillanceACT partner drugsMalaria-endemic countriesSentinel surveillance systemDrug surveillance dataAntimalarial drug resistanceSaharan AfricaPartner drugsCombination therapyAntimalarial resistanceSurveillance sitesMarker prevalenceResistance surveillanceMedian time lagMolecular surveillanceSystematic searchResistance-associated markersMean amountSub-Saharan countriesQuantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis
Pfeffer DA, Ley B, Howes RE, Adu P, Alam MS, Bansil P, Boum Y, Brito M, Charoenkwan P, Clements A, Cui L, Deng Z, Egesie OJ, Espino FE, von Fricken ME, Hamid MMA, He Y, Henriques G, Khan WA, Khim N, Kim S, Lacerda M, Lon C, Mekuria AH, Menard D, Monteiro W, Nosten F, Oo NN, Pal S, Palasuwan D, Parikh S, Pasaribu A, Poespoprodjo JR, Price DJ, Roca-Feltrer A, Roh ME, Saunders DL, Spring MD, Sutanto I, Ley-Thriemer K, Weppelmann TA, von Seidlein L, Satyagraha AW, Bancone G, Domingo GJ, Price RN. Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis. PLOS Medicine 2020, 17: e1003084. PMID: 32407380, PMCID: PMC7224463, DOI: 10.1371/journal.pmed.1003084.Peer-Reviewed Original ResearchConceptsG6PD activity measurementsG6PD activityDiagnostic Accuracy Studies-2 toolDormant liver stagesRisk of biasGlucose-6-phosphate dehydrogenase deficiencyStudy-level heterogeneityNormal control samplesReference diagnostic methodInter-study variabilityGlucose-6-phosphate dehydrogenase activityMalaria patientsHaematological conditionsLiver stagesRadical cureP. ovalePlasmodium vivaxPubMed searchIntermediate deficiencySystematic reviewDiagnostic thresholdMale medianStudy participantsMedian activityDiagnostic implicationsAn Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment
Francis J, Barnes KI, Workman L, Kredo T, Vestergaard LS, Hoglund RM, Byakika-Kibwika P, Lamorde M, Walimbwa SI, Chijioke-Nwauche I, Sutherland CJ, Merry C, Scarsi KK, Nyagonde N, Lemnge MM, Khoo SH, Bygbjerg IC, Parikh S, Aweeka FT, Tarning J, Denti P. An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment. Antimicrobial Agents And Chemotherapy 2020, 64: 10.1128/aac.02394-19. PMID: 32071050, PMCID: PMC7179577, DOI: 10.1128/aac.02394-19.Peer-Reviewed Original ResearchConceptsDrug-drug interactionsAntiretroviral therapyDolutegravir-based antiretroviral therapyPotential drug-drug interactionsDay 7 concentrationsIndividual participant dataConcomitant efavirenzLopinavir-ritonavirLumefantrine exposureLumefantrine regimenAntituberculosis treatmentUncomplicated malariaAntiretroviral treatmentHIV infectionTreatment failurePopulation pharmacokineticsLumefantrine concentrationsLarger body weightBody weightEfavirenzParticipant dataLumefantrineMalariaAdult participantsRifampinEfavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.
Hughes E, Mwebaza N, Huang L, Kajubi R, Nguyen V, Nyunt MM, Orukan F, Mwima MW, Parikh S, Aweeka F. Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 83: 140-147. PMID: 31929402, PMCID: PMC7061940, DOI: 10.1097/qai.0000000000002237.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAlkynesAnti-HIV AgentsAntimalarialsAnti-Retroviral AgentsArtemetherArtemether, Lumefantrine Drug CombinationArtemisininsBenzoxazinesCyclopropanesDrug CombinationsDrug InteractionsFemaleHIV InfectionsHumansLumefantrineMalariaMalaria, FalciparumPregnancyProspective StudiesUgandaYoung AdultConceptsEfavirenz-based antiretroviral therapyImpact of efavirenzPregnant womenArtemether-lumefantrineMalaria treatmentAntiretroviral therapyEfavirenz therapyIntensive PK evaluationPK exposure parametersPlasmodium falciparum malariaEffect of efavirenzActive metabolite dihydroartemisininAntimalarial exposureClinical responseFalciparum malariaPregnant HIVTreatment regimenNonsignificant reductionClinical pharmacokinetic studiesPK evaluationDrug interactionsLumefantrine concentrationsHIVTreatment durationPK samples
2019
Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis
Ley B, Satyagraha A, Rahmat H, von Fricken ME, Douglas NM, Pfeffer DA, Espino F, von Seidlein L, Henriques G, Oo NN, Menard D, Parikh S, Bancone G, Karahalios A, Price RN. Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis. PLOS Medicine 2019, 16: e1002992. PMID: 31834890, PMCID: PMC6910667, DOI: 10.1371/journal.pmed.1002992.Peer-Reviewed Original ResearchConceptsNegative predictive valueGlucose-6-phosphate dehydrogenase deficiencyIndividual participant dataSystematic reviewHigh negative predictive valueDehydrogenase deficiencyRandom-effects bivariate modelPrevalence of G6PDdDrug-induced haemolysisCapillary blood samplesRapid diagnostic testsPositive likelihood ratioNegative likelihood ratioLikelihood ratioVivax malariaVenous bloodEndemic settingsInclusion criteriaPooled estimatesBlood samplesRadical curePredictive valueWide geographical representationMale medianRoutine setting
2016
Time series analysis of malaria in Afghanistan: using ARIMA models to predict future trends in incidence
Anwar MY, Lewnard JA, Parikh S, Pitzer VE. Time series analysis of malaria in Afghanistan: using ARIMA models to predict future trends in incidence. Malaria Journal 2016, 15: 566. PMID: 27876041, PMCID: PMC5120433, DOI: 10.1186/s12936-016-1602-1.Peer-Reviewed Original ResearchConceptsMalaria incidenceScreening for Glucose-6-Phosphate Dehydrogenase Deficiency Using Three Detection Methods: A Cross-Sectional Survey in Southwestern Uganda.
Roh ME, Oyet C, Orikiriza P, Wade M, Mwanga-Amumpaire J, Boum Y, Kiwanuka GN, Parikh S. Screening for Glucose-6-Phosphate Dehydrogenase Deficiency Using Three Detection Methods: A Cross-Sectional Survey in Southwestern Uganda. American Journal Of Tropical Medicine And Hygiene 2016, 95: 1094-1099. PMID: 27672207, PMCID: PMC5094223, DOI: 10.4269/ajtmh.16-0552.Peer-Reviewed Original ResearchMeSH KeywordsChild, PreschoolCross-Sectional StudiesDiagnostic Tests, RoutineFemaleGene FrequencyGlucosephosphate DehydrogenaseGlucosephosphate Dehydrogenase DeficiencyHumansInfantMalariaMalaria, FalciparumMalaria, VivaxMalePoint-of-Care SystemsPrevalencePrimaquineRural PopulationSensitivity and SpecificityUgandaUrban PopulationConceptsG6PDd prevalenceGlucose-6-phosphate dehydrogenase deficiencyDehydrogenase deficiencySingle-dose primaquinePlasmodium falciparum transmissionSouthwestern UgandaPlasmodium ovale infectionNegative predictive valueMonths of ageCross-sectional surveyViable screening testOvale infectionsDiagnostic modalitiesStandard quantitative assayLow prevalenceRadical curePlasmodium vivaxPredictive valueSectional surveyCare testScreening testPrevalenceSevere deficiencyPrimaquineEnzyme activityAsymptomatic Plasmodium Infections in Children in Low Malaria Transmission Setting, Southwestern Uganda - Volume 22, Number 8—August 2016 - Emerging Infectious Diseases journal - CDC
Roh ME, Oyet C, Orikiriza P, Wade M, Kiwanuka GN, Mwanga-Amumpaire J, Parikh S, Boum Y. Asymptomatic Plasmodium Infections in Children in Low Malaria Transmission Setting, Southwestern Uganda - Volume 22, Number 8—August 2016 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2016, 22: 1494-1498. PMID: 27434741, PMCID: PMC4982177, DOI: 10.3201/eid2208.160619.Peer-Reviewed Original ResearchConceptsMicroscopy-positive samplesLow malaria transmission settingsInfectious Diseases journal - CDCAsymptomatic Plasmodium infectionsMalaria transmission settingsRapid diagnostic testsP. falciparum parasitesRoutine diagnostic testingP. ovale parasitesAsymptomatic childrenPlasmodium infectionPlasmodium malariaeP. malariaeTransmission settingsFalciparum parasitesDiagnostic testingDiagnostic testsMalariaeChildrenParasitesInfectionRethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study
Sambol NC, Tappero JW, Arinaitwe E, Parikh S. Rethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study. PLOS ONE 2016, 11: e0154623. PMID: 27182702, PMCID: PMC4868321, DOI: 10.1371/journal.pone.0154623.Peer-Reviewed Original ResearchConceptsPopulation pharmacokinetic modelWeekly dosingUncomplicated Plasmodium falciparum malariaSteady-state trough concentrationsPharmacokinetic modelYoung childrenStandard therapeutic dosesYoung Ugandan childrenFirst-line therapyPlasmodium falciparum malariaFuture trial designPeak concentrationPlasma concentration-time profilesPercent of childrenConcentration-time profilesPiperaquine concentrationsMalaria chemopreventionBreakthrough infectionsMonthly administrationTrough concentrationsAcute treatmentFalciparum malariaLoading doseChemopreventive regimensInitial dosingAntiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children
Parikh S, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Gao Q, Li F, Were M, Kakuru A, Achan J, Mwebaza N, Aweeka FT. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children. Clinical Infectious Diseases 2016, 63: 414-422. PMID: 27143666, PMCID: PMC4946019, DOI: 10.1093/cid/ciw291.Peer-Reviewed Original ResearchConceptsArtemether-lumefantrine treatmentLPV/rRecurrent malariaLumefantrine exposureDrug exposureCritical drug-drug interactionsFirst-line antiretroviral therapy regimensArtemisinin-based combination therapyLopinavir/ritonavirAntiretroviral therapy regimensPlasmodium falciparum malariaHuman immunodeficiency virusDay 7 concentrationsMalaria-endemic regionsDrug-drug interactionsAntimalarial exposureAntimalarial componentPharmacokinetic samplingArtemether-lumefantrineFalciparum malariaClinical outcomesDosing regimensTherapy regimensImmunodeficiency virusCombination therapy
2015
Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin‐Piperaquine for Uncomplicated Malaria
Sambol N, Yan L, Creek D, McCormack S, Arinaitwe E, Bigira V, Wanzira H, Kakuru A, Tappero J, Lindegardh N, Tarning J, Nosten F, Aweeka F, Parikh S. Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin‐Piperaquine for Uncomplicated Malaria. Clinical Pharmacology & Therapeutics 2015, 98: 87-95. PMID: 25732044, PMCID: PMC5088713, DOI: 10.1002/cpt.104.Peer-Reviewed Original ResearchConceptsUncomplicated malariaPopulation pharmacokineticsYoung Ugandan childrenWeight-based dosingChildren 6 monthsAge-specific guidelinesClearance/bioavailabilityFirst-order absorptionDihydroartemisinin-PiperaquinePiperaquine exposureMalaria episodesProspective trialOral dosesUgandan childrenPlasma concentrationsThree-compartment modelDay 7High dosesAge groupsEarly childhoodPiperaquineDosingPharmacokineticsMalariaPhysiological changes